In fact, plasma levels of CcL2 in CRPS patients were found to show no correlation with the duration of the CRPS [37], and CSF levels of CcL2 and GFAP were found to be upregulated in only 50% of patients [38], suggesting that mechanisms other than persistent chemokine activation are at play. The gene discussed is CCL2; the disease is complex regional pain syndrome.